RSV Inhibitor

IDB-002 is a human monoclonal antibody (mAb) targeting F/Fusion glycoprotein F0. IDB-002 can be used in respiratory syncytial virus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).

RSV L-protein-IN-2 (Compound A) is a noncompetitive RSV polymerase inhibitor (IC₅₀: 4.5 μM). RSV L-protein-IN-2 shows antiviral activity against long RSV strains (EC₅₀: 1.3 μM).

Antiviral agent 58 (Compound J1) is an orally active antiviral agent with broad-spectrum antiviral activity against enveloped viruses, including influenza A virus (IAV), respiratory syncytial virus (RSV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), human coronavirus OC43 (HCoV-OC43), herpes simplex virus type 1 (HSV-1), and HSV-2.

Roflumilast (Standard) is the analytical standard of Roflumilast. This product is intended for research and analytical applications. Roflumilast (APTA-2217) is a selective PDE4 inhibitor with IC₅₀s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells.

BTA-9881 (MEDI-564) is a RSV inhibitor, with an EC₅₀: 48 nM, 59 nM and 160 nM for RSV A2, RSV Long, and RSV B1. BTA-9881 has favorable pharmacokinetics property.

RSV fusion protein IN-1 is an orally active RSV pre-fusion F protein inhibitor with an IC₅₀ of 0.10 nM against RSV. RSV fusion protein IN-1 forms stable hydrogen bonds and π-π stacking interactions with pre-fusion F protein to block viral fusion and entry. RSV fusion protein IN-1 suppresses RSV F protein expression in epithelial cells. RSV fusion protein IN-1 reduces viral burden in the lungs of RSV-infected murine models.RSV fusion protein IN-1 can be used for the research of respiratory syncytial virus (RSV) infection.

Ethyl (S)-2-aminobutanoate hydrochloride (Ethyl (2S)-2-aminobutanoate hydrochloride) is an antiviral compound. Ethyl (S)-2-aminobutanoate hydrochloride exhibits antiviral activity against RSV A2. Ethyl (S)-2-aminobutanoate hydrochloride can be used in research related to respiratory syncytial virus and DENV-2.

GS-646089 is a broad-spectrum antiviral nucleoside analog that exhibits significant inhibitory activity against respiratory syncytial virus (RSV), human metapneumovirus (hMPV), rhinovirus (enterovirus) and enteroviruses. The IC₅₀ of GS-646089 targeting RNA-dependent RNA polymerase (RdRp) ranges from 43 to 46 nM. GS-646089 blocks viral replication by being converted into a triphosphate metabolite intracellularly, which competes with ATP for incorporation into nascent RNA strands and acts as an immediate chain terminator. GS-646089 is the parent compound of the double prodrug GS-7682 (HY-161877), and is used in studies of acute respiratory viral infections and infections caused by related pathogens.

JNJ-7184 is a non-nucleoside inhibitor of the RSV-Large (L) polymerase, with the pEC₅₀ and pCC₅₀ of 7.86 and 4.29 in Hela cells, respectively. JNJ-7184 prevents RSV replication and transcription by inhibiting initiation or early elongation.

Ac-CoA Synthase-IN-1 (Standard) is the analytical standard of Ac-CoA Synthase-IN-1 (HY-104032). This product is intended for research and analytical applications. Ac-CoA Synthase-IN-1 is a potent, reversible acetate-dependent acetyl-CoA synthetase 2 (ACSS2) inhibitor with an IC₅₀ of 0.6 μM. Ac-CoA Synthase-IN-1 inhibits the respiratory syncytial virus (RSV).

Lonafarnib (Standard) (Sch66336 (Standard)) is the analytical standard of Lonafarnib (HY-15136). This product is intended for research and analytical applications. Lonafarnib (Sch66336) is an orally active, blood-brain barrier penetrant farnesyltransferase (FPTase) inhibitor. Lonafarnib increases the phosphorylation levels of Akt, CaMKII and CREB, upregulates BDNF expression in the hippocampus, elevates the content of α7nAChR on cell membranes, and blocks the isoprenylation of H-Ras. Lonafarnib repairs synapses and reverses spatial memory deficits in Aβ1-42 model mice. Lonafarnib inhibits RSV fusion and replication, and alleviates virus-induced lung injury. Lonafarnib activates the lysosomal and autophagic pathways, and reduces the phosphorylation and aggregation of tau. Lonafarnib acts synergistically with Sorafenib (HY-10201) to promote apoptosis, and inhibits the proliferation and invasion of melanoma cells. Lonafarnib inhibits the farnesylation of progerin, repairs nuclear membrane defects, and activates the cGAS-STING-STAT1 signaling pathway. Lonafarnib can be used in research related to diseases including Alzheimer's disease, viral infections, melanoma, and progeria.

Ziresovir (Standard) is the analytical standard of Ziresovir (HY-109142). This product is intended for research and analytical applications. Ziresovir (AK0529;RO-0529) is a potent, selective, and orally bioavailable respiratory syncytial virus (RSV) fusion (F) protein (RSV F) protein inhibitor. Ziresovir shows anti-RSV activity (EC₅₀=3 nM) and highlights pharmacoK_inetics in animal species.

AZ-27 is a respiratory syncytial virus (RSV) inhibitor. AZ-27 can differentially suppress various RSV polymerase activities at the promoter, thereby inhibiting the early stages of mRNA transcription and genome replication by targeting the promoter.

RSV L-protein-6 (Compound 19a) is a respiratory syncytial virus polymerase inhibitor, with an IC₅₀ of 13 nM in SPA primer extensions enzymatic assay. RSV L-protein-6 can inhibit RSV replication in Hela cells.

AZD-4316 is a respiratory syncytial virus (RSV) L protein inhibitor. AZD-4316 has an inhibitory effect on RSV A subtypes (such as strain A2) and can effectively block viral replication in the early stage of infection (the viral entry stage). AZD-4316 is inactive when administered 12-24 hours after infection. AZD-4316 can be used for the research of RSV infection.